Quick Facts

• Primary Use: May help with symptoms related to chronic venous and lymphatic insufficiency.
• Therapeutic Domains: Symptomatic management of heavy legs, pain, and nocturnal leg cramps.
• Additional Use: Used for the symptomatic management of symptoms associated with hemorrhoids.

Venotrex is a medication indicated for the symptomatic treatment of conditions related to venous and lymphatic insufficiency, particularly in the lower limbs. Its primary application may offer relief from common symptoms such as a feeling of heavy legs, localized discomfort, and nocturnal cramps. These indications are associated with conditions including varicose veins and other manifestations of compromised venous return.

Clinical experience indicates a potential role in vascular support, which may contribute to the maintenance of healthy capillaries and veins. Furthermore, the medication is used for the symptomatic management of the exacerbation of symptoms related to hemorrhoids. Treatment selection and planning should be determined by a qualified healthcare professional.

Who Can and Cannot Use Venotrex?

The official eligibility profile for Venotrex (Troxerutin/Oxerutines) is strictly defined by regulatory authorities based on age, underlying conditions, and physiological status. The medicine is approved for use in adults aged 18 years and older.

Contraindications and Restrictions

Venotrex is strictly contraindicated for individuals with a known hypersensitivity or allergy to the active substance, Troxerutin, or any of the formulation's inactive ingredients.

The medicine must not be used to treat swelling (oedema) in the lower limbs if the swelling is caused by underlying heart, kidney, or liver disease. The medicine is not effective for non-venous oedema, and treatment must address the primary organ dysfunction.

Population and Physiological Status

• Children and Adolescents: Use in individuals under 18 years of age is not recommended because safety and efficacy data have not been established.
• Pregnancy: Use during the first trimester is not recommended. Use in the second and third trimesters is conditional and requires medical approval.
• Breastfeeding: Use is generally not recommended without consulting a healthcare professional.

Interactions with other medicines and products

This section summarizes the official interaction profile for Troxerutin (Venotrex) as documented in authoritative governmental regulatory sources, such as the Summary of Product Characteristics (SmPC) and equivalent prescribing information.

The regulatory profile for this established phlebotonic agent is primarily characterized by the absence of specific, formal interaction warnings in the official labeling. The drug is generally considered to have no known clinically relevant interaction profile requiring mandatory cautionary statements across major regulatory domains.

Official Interaction Profile Summary

Interaction Domain	Regulatory Status (Official Documentation)
Contraindicated Combinations	None explicitly documented.
Metabolic Interactions (CYP Enzymes)	Not specified. Official labeling is silent regarding Troxerutin's role as an inhibitor, inducer, or substrate of major Cytochrome P450 enzymes.
Pharmacodynamic Interactions	None explicitly documented.
Timing / Separation Rules	No mandatory time separation or spacing requirements are documented.
Food, Alcohol, or Herbal Products	No explicit restrictions or warnings are documented in the official regulatory interaction sections.
Exposure Modification	No substances are listed by regulators as formally increasing or decreasing Troxerutin plasma concentrations (AUC/Cmax).

The official interaction section is structured by the lack of documented constraints rather than a list of specific interacting agents. Regulatory authorities have not mandated specific drug-drug, metabolic, or timing-based interaction statements, which reflects the conclusion that no clinically significant formal interactions require a specific cautionary statement.

How Venotrex works: Mechanism of Action

Capillary Endothelium Stabilization

The primary molecular action of the active constituent, aescin, involves the inhibition of key proteolytic enzymes, specifically hyaluronidase and elastase, localized within the vascular walls. This enzymatic inhibition maintains the structural integrity of the capillary and venule lining by limiting the degradation of the extracellular matrix components. This action results in a reduced capillary filtration rate and limits the extravasation of fluid and plasma proteins from the circulation into the surrounding interstitial tissues.

Modulation of Venous Tone and Fluid Dynamics

The mechanism extends to influencing underlying vascular dynamics by promoting a stabilizing effect on venous tone. This modulation of venous wall tension limits the extent of vascular distension. Through this multi-step cascade—enzyme inhibition ightarrow vascular wall stabilization ightarrow reduced fluid leakage—the drug influences the dynamics of fluid extravasation, contributing to the regulation of local fluid volume and resulting in the core physiological change of decreased interstitial fluid accumulation.

The administration of Troxerutin (Venotrex) involves specific routes, dosage amounts, and timing schedules. The medicine is used in two distinct forms: oral capsules or tablets intended for systemic administration, and topical gels for localized, dermal application.

Administration Protocol

Scope Item	Details
Route of administration	Oral (Systemic) and Topical (Dermal)
Dosing schedule	Oral: Adult daily dose range is typically 600 mg to 1200 mg. Topical: Apply a thin layer or a 4–5 cm column of gel per application.
Frequency pattern	Oral: Daily, administered in divided doses (e.g., once or twice daily). Topical: Applied 2 to 4 times per day.
Timing in relation to meals	Oral forms should be taken with or immediately after a meal.

Special Procedural Conditions

Oral dosing, when administered in divided amounts, must be managed consistently as a daily schedule. For topical application, the product should be gently rubbed into the affected area until it is fully absorbed. This dermal application must only be applied to intact skin and not to any broken or open wounds.

Age-Group Use Rules

There is a specific exclusion regarding age: the administration of Troxerutin is not recommended for children below the age of 14 years due to limitations in clinical data for this population.

These descriptions define the standardized approach to using the medicine.

Research Evidence / Overview of Studies for Venotrex (Troxerutin)

The information below provides an overview of the research and clinical studies conducted on Troxerutin, the active ingredient in Venotrex. It focuses on the types of evidence that exist and the areas where official research has concentrated, while maintaining a neutral, non-advisory perspective.

---

Evidence for Use in Chronic Venous Insufficiency (CVI)

Research exploring CVI symptoms, which includes the types of Randomized Controlled Trials (RCTs) and Systematic Reviews that have evaluated patient-reported discomforts and objective measures like leg swelling, has been the focus for this condition. These studies primarily enroll adult patients with diagnosed CVI, typically those experiencing symptoms like swelling and pain, and were used in research exploring how symptoms change over time.

Findings describe patterns observed in the studies where measurements of leg edema and patient-reported symptoms (such as leg pain and heaviness) were tracked and compared to initial baseline assessments. Long-term outcomes for this indication are not well characterized. Evidence quality varies across studies due to differences in design and dosage, a factor known as heterogeneity. The available data provide limited information for long-term outcomes or the persistence of observed patterns after the study intervals concluded.

---

Evidence for Symptomatic Management of Hemorrhoids

Troxerutin was studied for its use in contexts involving symptoms associated with hemorrhoidal disease. This research explored short-term symptom changes, focusing on conditions involving periods of heightened symptoms, such as an acute crisis. Studies were typically short-term RCTs that followed adult patients with acute symptoms.

A key research limitation in this area is the frequent use of combination products. Many studies involved Troxerutin administered alongside other venoactive agents, and the specific contribution of Troxerutin alone is therefore considered uncertain. Due to this, certainty remains low, and evidence is limited when considering the use of Troxerutin as a single-ingredient therapy for this condition.

---

Evidence Gaps and Areas of Research Uncertainty

Comparative evidence is lacking, meaning few studies directly compare Troxerutin against the newest available treatments or other non-medicinal management strategies. Data for certain groups remain limited or insufficient, including pregnant populations and children. Furthermore, long-term outcomes are not well characterized, as follow-up durations were limited, leaving uncertainty about extended use for these chronic conditions.

Key Studies & References

1. Double-blind, randomized clinical trial of troxerutin-carbazochrome in patients with hemorrhoids
2. Flavonoids mixture (diosmin, troxerutin, hesperidin) in the treatment of acute hemorrhoidal disease: a prospective, randomized, triple-blind, controlled trial.

Common questions about Venotrex (FAQ)

Q: Does Venotrex interact with common over-the-counter pain relievers?

According to the official interaction profile summary, regulatory documents generally state that Venotrex has no known clinically relevant interaction profile requiring specific cautionary statements. The regulatory profile generally states no known clinically relevant interaction profile with other medications.

---

Q: Are there known interactions between Venotrex and blood-thinning medicines?

Regulatory authorities have not mandated specific warnings or constraints regarding interactions between Venotrex and blood-thinning medicines (anticoagulants) in the official interaction profile summary. The official documentation is structured by the lack of documented constraints rather than a list of specific interacting agents.

---

Q: Is Venotrex designed for short-term or long-term use?

Studies and official information indicate that regulatory-supported research primarily focuses on symptom relief over limited periods. Official documents state that long-term outcomes for this indication are not well characterized due to limitations in study follow-up duration.

---

Q: Is Venotrex considered suitable for elderly patients?

According to official documentation, the medicine is approved for use in adults aged 18 years and older. There is no specific exclusion or mandatory warning cited in regulatory texts regarding the general elderly population beyond the standard adult approval.

---

Q: Is it normal to experience mild stomach upset when starting Venotrex?

Official documents classify abdominal discomfort and nausea as documented adverse reactions under Gastrointestinal Disorders. These effects are officially classified as Rare or Very Rare in regulatory documents.

---

Q: How does the official text describe the maximum recommended duration of use for Venotrex?

Official regulatory texts do not explicitly mandate a maximum duration of use for the medicine. The research summary notes that long-term outcomes are not well characterized, meaning the safety and efficacy of extended use beyond study periods are not defined in the evidence.

---

Q: Can Venotrex cause headaches or fatigue?

Official prescribing information lists headache and dizziness as reported effects under Nervous System Disorders, classified as Rare or Very Rare. The regulatory texts do not list fatigue as a documented adverse reaction.

---

Q: Is Venotrex a prescription drug, or is it available without a prescription?

The regulatory classification of Venotrex (Troxerutin) varies by country or region. The official labeling defines the legal status, which can range from a non-prescription (OTC) medicine to a pharmacy-only medicine in various territories where it is authorized.

---

Q: Does Venotrex contain any common allergens like gluten or lactose?

Official product information documents (such as the Summary of Product Characteristics, SmPC) include a List of excipients. This section provides a complete inventory of all ingredients, including any commonly known allergens like gluten or lactose. The complete list of ingredients is available for user review.

---

Q: What should be done if the appearance of the tablets changes?

Official patient information instructs users to not take the medicine if they notice a change in the appearance of the tablets, capsules, or gel. Regulatory guidance states the package should be returned to a pharmacist or doctor for assessment and appropriate disposal.

---

Q: Are there any specific warnings about driving or operating machinery while taking Venotrex?

Official product information addresses the effects on the ability to drive or operate machinery. Regulatory labeling typically states that no effects have been observed or reported, or advises caution due to potential dizziness, which is listed as a reported side effect.

---

Q: Is there any information on whether Venotrex impacts fertility?

Official product information typically addresses fertility under the section covering Fertility, pregnancy and lactation. Regulatory documents usually state that no effects on fertility have been documented or that animal studies have not indicated harmful effects.

---

Q: How is the quality of the active ingredient in Venotrex standardized in regulatory documents?

The active ingredient, Troxerutin, is a semi-synthetic flavonoid derivative whose quality is regulated by the relevant national pharmacopoeia standards. These procedures define the requirements for consistency and purity for the approved drug.

---

Q: Is Venotrex classified as a blood thinner?

Venotrex (Troxerutin) is officially classified as an Angioprotective and Phlebotonic agent, and a Capillary Stabilizing Agent within the WHO ATC system. It is not classified as an anticoagulant or antiplatelet medicine (commonly referred to as a blood thinner).

---

Q: Why do official documents state that a doctor or pharmacist consultation is needed before starting Venotrex?

The need for consultation is related to the regulatory constraint that Venotrex must not be used to treat swelling (oedema) that is caused by underlying heart, kidney, or liver disease. This means a medical assessment is required to determine the cause of swelling before use.

How to Store and Dispose of Venotrex (Troxerutin)

The official instructions for storing Venotrex are designed to maintain the product's stability and efficacy throughout its labeled shelf-life. The medication should be stored under specific environmental conditions and protected from contamination.

Storage Requirements

• Temperature: Store at a temperature typically not exceeding 25 C or 30 C and do not freeze.
• Protection: The medicine must be kept in its original container with the lid tightly closed to protect it from moisture and light.
• Child Safety: Venotrex must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Expired or unused Venotrex should be disposed of via a drug take-back program. If a program is unavailable, the medicine should be mixed with an unappealing substance, sealed in a bag, and then discarded in the household trash. Do not dispose of the medication by flushing it down a toilet or pouring it down a drain.